Trial · NCT02197897
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
NCT02197897, Phase 2, Completed, Baylor College of Medicine; results first posted 2021-01-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors. Trials, record NCT02197897. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02197897
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
- NCT number
- NCT02197897
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 15 participants, actual
- Lead sponsor
- Baylor College of Medicine
- Conditions
- Bladder Cancer
- Interventions
- Tamoxifen Citrate
- First posted
- 2014-07-23
- Last updated
- 2021-01-13
- Results first posted
- 2021-01-13
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion | 2.5 years | Evaluate the efficacy of tamoxifen for treatment of low/intermediate-risk bladder tumors, utilizing the RECIST criteria combined with the final biopsy of the marker lesion or the bed of the lesion in case of a complete response |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion | 2.5 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Evaluate the Efficacy for Treatment of Low/Intermediate- Risk Bladder Tumors, Assessing for the Clinical Response of the Marker Lesion | Tamoxifen | 13 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tamoxifen | 15 | |
| Overall Study | COMPLETED | Tamoxifen | 14 | |
| Overall Study | NOT COMPLETED | Tamoxifen | 1 |
Source ClinicalTrials.gov
Adverse events28
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hematuria | Blood and lymphatic system disorders | Tamoxifen | 3 | 13 | 3 |
| other | Urinary Tract Pain | Gastrointestinal disorders | Tamoxifen | 2 | 13 | 2 |
| other | Urinary Frequency | Renal and urinary disorders | Tamoxifen | 1 | 13 | 1 |
| other | Pain in Extremity | Musculoskeletal and connective tissue disorders | Tamoxifen | 2 | 13 | 2 |
| other | Flank Pain | Musculoskeletal and connective tissue disorders | Tamoxifen | 1 | 13 | 1 |
| other | Thromboembolic event | Cardiac disorders | Tamoxifen | 2 | 13 | 2 |
| other | Hypertension | Cardiac disorders | Tamoxifen | 1 | 13 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Tamoxifen | 2 | 13 | 3 |
| other | Sinus Bradycardia | Cardiac disorders | Tamoxifen | 1 | 13 | 1 |
| other | Sinus Tachycardia | Cardiac disorders | Tamoxifen | 1 | 13 | 1 |
1 to 10 of 28Source ClinicalTrials.gov
See all 28 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tamoxifen | 0 | 13 |
| Total, other adverse events | Tamoxifen | 5 | 13 |
| Total, serious adverse events | Tamoxifen | 0 | 13 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23CA160664 | ESTROGEN RECEPTOR TARGETED TREATMENT OF NON-MUSCLE INVASIVE BLADDER CANCER | GODOY, GUILHERME | BAYLOR COLLEGE OF MEDICINE | NATIONAL CANCER INSTITUTE | 2013 to 2016 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02197897
GET https://conductscience.org/api/trials/v1/NCT02197897/events?page=2